What's in Mylan Pharmaceuticals Inc's pipeline?

Mylan Pharmaceuticals Inc has 24 drugs in our index: 0 marketed, 0 filed, 7 in Phase 3, 1 in Phase 2, 16 in Phase 1.

Which companies overlap with Mylan Pharmaceuticals Inc's portfolio?

Top competitors by shared drug class: Pfizer, Bio-Thera Solutions, Grewal Eye Institute, Centus Biotherapeutics Limited, Cipla BioTec Pvt. Ltd..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/mylan-pharmaceuticals-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Mylan Pharmaceuticals Inc — Portfolio Competitive Intelligence Brief

Mylan Pharmaceuticals Inc pipeline: 0 marketed, 0 filed, 7 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 7 Phase 3 1 Phase 2 16 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
MYL-1701P	MYL-1701P	phase 3	G-CSF receptor agonist (pegylated biosimilar)	G-CSF receptor (GCSFR)	Oncology
Estrace® 0.01% cream	Estrace® 0.01% cream	phase 3	Estrogen replacement therapy	Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ)	Gynecology / Endocrinology
MYL-1701P, a proposed biosimilar to Eylea	MYL-1701P, a proposed biosimilar to Eylea	phase 3	Monoclonal antibody (fusion protein) / VEGF inhibitor / Biosimilar	VEGF-A, VEGF-B, PlGF (vascular endothelial growth factor and placental growth factor)	Ophthalmology
Estradiol Vaginal Cream, 0.01%	Estradiol Vaginal Cream, 0.01%	phase 3	Estrogen replacement therapy (local/vaginal)	Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ)	Gynecology / Menopause
Bevacizumab as MYL-1402O	Bevacizumab as MYL-1402O	phase 3	Monoclonal antibody; VEGF inhibitor; Antiangiogenic agent	VEGF (Vascular Endothelial Growth Factor)	Oncology
Bevacizumab as Avastin	Bevacizumab as Avastin	phase 3	VEGF inhibitor (monoclonal antibody)	VEGF (Vascular Endothelial Growth Factor)	Oncology
Transdermal system containing progestin	Transdermal system containing progestin	phase 3	Progestin contraceptive / Hormone replacement therapy	Progesterone receptor	Contraception / Women's Health

Therapeutic area mix

Oncology · 3
Contraception / Women's Health · 1
Gynecology / Endocrinology · 1
Gynecology / Menopause · 1
Ophthalmology · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Pfizer · 2 shared drug classes
Bio-Thera Solutions · 1 shared drug class
Grewal Eye Institute · 1 shared drug class
Centus Biotherapeutics Limited · 1 shared drug class
Cipla BioTec Pvt. Ltd. · 1 shared drug class
Eli Lilly and Company · 1 shared drug class
CONRAD · 1 shared drug class
Barnes Retina Institute · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Mylan Pharmaceuticals Inc:

Cite this brief

Drug Landscape (2026). Mylan Pharmaceuticals Inc — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/mylan-pharmaceuticals-inc. Accessed 2026-05-16.